Business Wire

Beren Therapeutics Announces FDA Acceptance of its New Drug Application for Adrabetadex in Infantile-Onset Niemann-Pick Disease Type C

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Beren Therapeutics P.B.C. ®, the parent company of Mandos LLC ® and leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, today ...
PharmiWeb

Beren Therapeutics Presents Data Supporting the Efficacy of Adrabetadex in Infantile-Onset NPC at 2026 ACMG Clinical Genetics Meeting

Treatment with adrabetadex reduced the annual rate of neurologic disease progression by 43%, in addition to previously ...
Morningstar

Beren Therapeutics Announces FDA Acceptance of its New Drug Application for Adrabetadex in Infantile-Onset Niemann-Pick Disease Type C

--If approved, adrabetadex would be the only therapy to directly target the underlying pathophysiology of Niemann-Pick disease type C (NPC) --Comprehensive NDA application includes data showing ...